LEUKOCARE Receives Growth Capital Funding and Strengthens its Board With Industry Experts

LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for proteins and other biologics, today announced the closing of its latest financing round providing growth capital to the company. The round was led by Swiss private equity firm LifeCare Partners together with a consortium of new investors.

The financing will primarily be used to fund market access activities for a number of development projects based on LEUKOCARE's Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.

Moreover, Gerhard Ries, Managing Partner with LifeCare Partners, and Jean-Paul Prieels will join the supervisory board. Dr. Prieels held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development.

LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology platform for the protection of biological compounds to allow the development of better products. The proprietary SPS® technologies are provided to development projects in pharma and medtech. LEUKOCARE's SPS® improve stability and quality of biologics like antibodies and vaccines in dry and liquid formulation and protect proteins in combination devices.

http://www.leukocare.com

LifeCare Partners

LifeCare Partners is an independent investment firm providing financing to private and public life science companies. Based in Basel, the LifeCare Partners has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.

 

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.

The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.